Wellington Management Group LLP Lowers Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Wellington Management Group LLP lessened its holdings in Immunocore Holdings plc (NASDAQ:IMCR) by 6.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,617,055 shares of the company’s stock after selling 431,778 shares during the period. Wellington Management Group LLP owned 13.23% of Immunocore worth $195,203,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its stake in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after purchasing an additional 960 shares during the period. NEOS Investment Management LLC increased its holdings in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares during the last quarter. XTX Topco Ltd lifted its stake in Immunocore by 72.9% in the 3rd quarter. XTX Topco Ltd now owns 15,459 shares of the company’s stock worth $481,000 after purchasing an additional 6,516 shares in the last quarter. Verition Fund Management LLC purchased a new position in shares of Immunocore during the third quarter valued at about $739,000. Finally, Assetmark Inc. increased its holdings in shares of Immunocore by 5.3% in the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock worth $949,000 after purchasing an additional 1,616 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Up 2.8 %

Shares of NASDAQ IMCR opened at $29.43 on Thursday. Immunocore Holdings plc has a 1 year low of $27.19 and a 1 year high of $64.47. The firm has a 50-day simple moving average of $29.99 and a two-hundred day simple moving average of $30.87. The company has a market cap of $1.47 billion, a P/E ratio of -30.98 and a beta of 0.79. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Insider Transactions at Immunocore

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the acquisition, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 9.10% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.